JP Morgan analyst Matthew Boss reiterated an Overweight rating for Viking Holdings, raising the price target to $58 from $50.

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst JPMorgan highlights valuation resets for Viking and Structure Therapeutics ...

Viking Therapeutics (NASDAQ ... It is also an orally administered treatment, giving it an advantage over competing products on the American market that are already Food and Drug Administration ...

Customers of Norwegian footwear brand Viking Outdoor Footwear will soon be able to scan a unique QR code on individual ...

Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough bump in the road? First, let's get to the bottom of what Merck did to provoke ...